Tuyển tập các báo cáo nghiên cứu về y học được đăng trên tạp chí y học General Psychiatry cung cấp cho các bạn kiến thức về ngành y đề tài: ncremental cost effectiveness of proton pump inhibitors for the prevention of non-steroidal anti-inflammatory drug ulcers: a pharmacoeconomic analysis linked to a case-control study. | Available online http content 10 6 R144 Research article Incremental cost effectiveness of proton pump inhibitors for the prevention of non-steroidal anti-inflammatory drug ulcers a pharmacoeconomic analysis linked to a case-control study Harald E Vonkeman1 Louise MA Braakman-Jansen2 Rogier M Klok3 Maarten J Postma3 Jacobus RBJ Brouwers3 and Mart AFJ van de Laar1 Department of Rheumatology and Clinical Immunology Medisch Spectrum Twente and University of Twente Ariensplein 1 7511 JX Enschede The Netherlands department of Psychology Communication of Health Risk University of Twente Citadel 7500 AE Enschede The Netherlands 3Groningen University Institute for Drug Exploration GUIDE Department of Social Pharmacy Pharmacoepidemiology and Pharmacotherapy Groningen University Antonius Deusinglaan 1 9713 AV Groningen The Netherlands Corresponding author Harald E Vonkeman Received 25 May 2008 Revisions requested 1 Jul 2008 Revisions received 21 Nov 2008 Accepted 16 Dec 2008 Published 16 Dec 2008 Arthritis Research Therapy 2008 10 R144 doi ar2577 This article is online at http content 10 6 R144 2008 Vonkeman et al. licensee BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License http licenses by which permits unrestricted use distribution and reproduction in any medium provided the original work is properly cited. Open Access Abstract Introduction We estimated the cost effectiveness of concomitant proton pump inhibitors PPIs in relation to the occurrence of non-steroidal anti-inflammatory drug NSAID ulcer complications. Methods This study was linked to a nested case-control study. Patients with NSAID ulcer complications were compared with matched controls. Only direct medical costs were reported. For the calculation of the incremental cost effectiveness ratio we extrapolated the data to 1 000 patients .
